Crossmark

Longitudinal monitoring of denosumab-associated bone changes by REMS in postmenopausal women with ER-positive breast cancer receiving aromatase inhibitors.

Crossref DOI link: https://doi.org/10.1007/s40520-026-03402-7

Published Online: 2026-04-20

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Caffarelli, Carla

Forcignanò, Rosachiara

Muratore, Maurizio

Gonnelli, Stefano
License Information

Text and Data Mining valid from 2026-04-20

Accepted Manuscript valid from 2026-04-20
More Information

Article History

Received: 30 March 2026

Accepted: 8 April 2026

First Online: 20 April 2026

Declarations

:

: The authors declare no competing interests.

: Nothing to declare.

: This study was approved by the Ethics Review Board of the participating hospital, and it was conducted in accordance with the ethical standards of the Declaration of Helsinki (1964).

: Informed consent for participation and publication has been obtained from all the participants included in the study.

Document is current

Any future updates will be listed below